UAE health AI policy moves medical AI toward regulated systems

Policy Work Became National Direction

On 17 February 2026, the Ministry of Health and Prevention organized a specialized workshop on developing the National Policy for the Promotion of Smart Health Services and Artificial Intelligence in the Health Sector. The workshop was a consultation and policy development step. The approved sources do not establish a prior national medical AI pilot phase, so the supported conclusion is that the UAE moved from policy development toward approved governance.

MoHAP said the policy work aimed to formulate a comprehensive national framework that encourages institutional adoption of artificial intelligence in the health sector. The stated policy areas included data quality, privacy protection, measurement of public health impact, patient experience, governance and leadership, partnerships, integration, data sharing, digital infrastructure, professional skills, cybersecurity, transparency, and accountability.

The workshop included federal and local health bodies, Emirates Health Services, the AI Office in the Cabinet, universities, and technology companies. That mix matters for UAE businesses because health AI is being treated as a system issue that involves regulators, providers, data holders, academic institutions, and suppliers. It is not presented in the approved sources as a narrow software procurement matter or as evidence of completed national deployment.

Cabinet Approval Raised The Commitment

On 18 May 2026, the UAE Cabinet approved the National Policy for Advancing Digital Healthcare Services and Artificial Intelligence in the Healthcare Sector. The Cabinet described the policy as a comprehensive framework to build an integrated national health system supported by AI systems and models, with the aim of improving health and wellbeing for community members.

The Cabinet source states that the policy aims to expand the application of digital technologies and artificial intelligence across preventive, curative, rehabilitative, and operational levels. It also refers to smart health infrastructure, national cadres with advanced AI competencies, security, ethics, and data governance for AI applications in the health sector.

This approval should not be read as evidence that every hospital, clinic, insurer, or health supplier in the UAE is already operating under a completed new AI law. The official record supports a narrower conclusion. A national policy has been approved, and a federal law has been approved for drafting. Implementation details, the final legal text, and binding sector obligations will depend on later regulatory steps.

The Draft Law Is The Business Signal

The Cabinet also approved the drafting of a Federal Law to regulate smart health applications and the use of artificial intelligence in the health sector. The planned law is described as a unified legal framework for the development, licensing, accreditation, operation, and use of AI powered health systems.

The same Cabinet statement says the federal law will address health data governance, safety and quality standards, legal liability provisions, patient rights protections, and federal local coordination mechanisms. These areas are directly relevant to business planning because they indicate the issues that health AI projects will need to handle before they can scale responsibly in a regulated environment.

For healthcare providers, insurers, laboratories, vendors, and investors, the practical reading is not that new obligations are already final. It is that the UAE policy direction has become more formal. Organizations evaluating AI in clinical, administrative, preventive, rehabilitative, or operational settings should be ready to explain intended use, data handling, privacy controls, safety measures, human oversight, and accountability once more detailed rules are issued. That is business analysis based on the policy areas named by official sources.

Governance Will Shape Adoption

The approved sources do not provide vendor claims, clinical trial results, research performance figures, or evidence that a specific AI product has been released or deployed nationwide. They also do not document general availability, early access, previews, or completed rollouts of particular medical AI systems. The article therefore does not treat the policy as proof of product readiness or sector wide implementation.

What the sources do show is a clear governance agenda. MoHAP framed the policy work around institutional adoption, privacy, data quality, public health impact, patient experience, cybersecurity, transparency, and accountability. The Cabinet then approved a national policy and approved drafting a federal law covering licensing, accreditation, operation, use, data governance, safety, quality, liability, patient rights, and coordination between federal and local authorities.

The Cabinet also approved a broader roles and responsibilities framework for federal ministries and entities in implementing the Agentic AI Project. That framework concerns federal government implementation and assessment rather than a private health sector compliance rule. For UAE business readers, its relevance is limited but useful. It reinforces the direction of travel toward assigned responsibility, measurable implementation, and governance around AI systems in public institutions.

The main business implication is disciplined preparation. Health AI buyers and suppliers should avoid treating policy approval as the same thing as enacted legislation or completed deployment. They should instead use the policy record to prepare stronger evidence, controls, documentation, and accountability models for AI systems that may enter regulated health settings once the planned legal framework advances.